Matthieu Pelletier-Galarneau1, Yoann Petibon1, Chao Ma1, Paul Han1, Sally Ji Who Kim1, Felicitas J Detmer1, Daniel Yokell1, Nicolas Guehl1, Marc Normandin1, Georges El Fakhri2, Nathaniel M Alpert3. 1. Department of Radiology, Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, 125 Nashua Street, #6604, Boston, MA, 02114, USA. 2. Department of Radiology, Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, 125 Nashua Street, #6604, Boston, MA, 02114, USA. ELFAKHRI.GEORGES@mgh.harvard.edu. 3. Department of Radiology, Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, 125 Nashua Street, #6604, Boston, MA, 02114, USA. alpert@pet.mgh.harvard.edu.
Abstract
PURPOSE: Alteration in mitochondrial membrane potential (ΔΨm) is an important feature of many pathologic processes, including heart failure, cardiotoxicity, ventricular arrhythmia, and myocardial hypertrophy. We present the first in vivo, non-invasive, assessment of regional ΔΨm in the myocardium of normal human subjects. METHODS: Thirteen healthy subjects were imaged using [18F]-triphenylphosphonium ([18F]TPP+) on a PET/MR scanner. The imaging protocol consisted of a bolus injection of 300 MBq followed by a 120-min infusion of 0.6 MBq/min. A 60 min, dynamic PET acquisition was started 1 h after bolus injection. The extracellular space fraction (fECS) was simultaneously measured using MR T1-mapping images acquired at baseline and 15 min after gadolinium injection with correction for the subject's hematocrit level. Serial venous blood samples were obtained to calculate the plasma tracer concentration. The tissue membrane potential (ΔΨT), a proxy of ΔΨm, was calculated from the myocardial tracer concentration at secular equilibrium, blood concentration, and fECS measurements using a model based on the Nernst equation. RESULTS: In 13 healthy subjects, average tissue membrane potential (ΔΨT), representing the sum of cellular membrane potential (ΔΨc) and ΔΨm, was - 160.7 ± 3.7 mV, in excellent agreement with previous in vitro assessment. CONCLUSION: In vivo quantification of the mitochondrial function has the potential to provide new diagnostic and prognostic information for several cardiac diseases as well as allowing therapy monitoring. This feasibility study lays the foundation for further investigations to assess these potential roles. Clinical trial identifier: NCT03265431.
PURPOSE: Alteration in mitochondrial membrane potential (ΔΨm) is an important feature of many pathologic processes, including heart failure, cardiotoxicity, ventricular arrhythmia, and myocardial hypertrophy. We present the first in vivo, non-invasive, assessment of regional ΔΨm in the myocardium of normal human subjects. METHODS: Thirteen healthy subjects were imaged using [18F]-triphenylphosphonium ([18F]TPP+) on a PET/MR scanner. The imaging protocol consisted of a bolus injection of 300 MBq followed by a 120-min infusion of 0.6 MBq/min. A 60 min, dynamic PET acquisition was started 1 h after bolus injection. The extracellular space fraction (fECS) was simultaneously measured using MR T1-mapping images acquired at baseline and 15 min after gadolinium injection with correction for the subject's hematocrit level. Serial venous blood samples were obtained to calculate the plasma tracer concentration. The tissue membrane potential (ΔΨT), a proxy of ΔΨm, was calculated from the myocardial tracer concentration at secular equilibrium, blood concentration, and fECS measurements using a model based on the Nernst equation. RESULTS: In 13 healthy subjects, average tissue membrane potential (ΔΨT), representing the sum of cellular membrane potential (ΔΨc) and ΔΨm, was - 160.7 ± 3.7 mV, in excellent agreement with previous in vitro assessment. CONCLUSION: In vivo quantification of the mitochondrial function has the potential to provide new diagnostic and prognostic information for several cardiac diseases as well as allowing therapy monitoring. This feasibility study lays the foundation for further investigations to assess these potential roles. Clinical trial identifier: NCT03265431.
Authors: Akos A Gerencser; Christos Chinopoulos; Matthew J Birket; Martin Jastroch; Cathy Vitelli; David G Nicholls; Martin D Brand Journal: J Physiol Date: 2012-04-10 Impact factor: 5.182
Authors: Daniel H Paulus; Harald H Quick; Christian Geppert; Matthias Fenchel; Yiqiang Zhan; Gerardo Hermosillo; David Faul; Fernando Boada; Kent P Friedman; Thomas Koesters Journal: J Nucl Med Date: 2015-05-29 Impact factor: 10.057
Authors: Daniel R Messroghli; Aleksandra Radjenovic; Sebastian Kozerke; David M Higgins; Mohan U Sivananthan; John P Ridgway Journal: Magn Reson Med Date: 2004-07 Impact factor: 4.668
Authors: Milica Momcilovic; Anthony Jones; Sean T Bailey; Christopher M Waldmann; Rui Li; Jason T Lee; Gihad Abdelhady; Adrian Gomez; Travis Holloway; Ernst Schmid; David Stout; Michael C Fishbein; Linsey Stiles; Deepa V Dabir; Steven M Dubinett; Heather Christofk; Orian Shirihai; Carla M Koehler; Saman Sadeghi; David B Shackelford Journal: Nature Date: 2019-10-30 Impact factor: 49.962
Authors: Felicitas J Detmer; Nathaniel M Alpert; Sung-Hyun Moon; Maeva Dhaynaut; J Luis Guerrero; Nicolas J Guehl; Fangxu Xing; Pedro Brugarolas; Timothy M Shoup; Marc D Normandin; Matthieu Pelletier-Galarneau; Georges El Fakhri; Yoann Petibon Journal: Sci Rep Date: 2022-04-12 Impact factor: 4.379